⌘+K

Equity Story

Near term

6-12 MONTHS

Continued pipeline progression of the existing clinical-stage development programmes of FG001 in high-grade glioma and oral head and neck cancer. We expect topline results in H1 2027 from the Phase II (part 2) trials for FG001 in high-grade glioma (CT-006) and oral head and neck cancer (CT-005). Also, we believe there is a high likelihood of FluoGuide announcing another partnership within the next 12 months.

Long term

6+ YEARS

The long-term value creation depends on achieving regulatory approvals of FG001 in high-grade glioma and oral head and neck cancer and successfully executing on the go-to market strategy. In addition to high-grade glioma and oral head and neck cancer, we believe FluoGuide could initiate Phase II trials across adjacent oncology indications, aiming at expanding the label.

Key risks

  • Regulatory delays.

  • Cost overruns.

  • Dependency on partnerships.

Fair value range

Price

Fair range high value

Fair range low value

Our fair value range is based on risk-adjusted sales for FG001 in high-grade glioma, low-grade glioma, meningioma and oral head and neck cancer. The range is driven by the H1 2027 topline readouts of CT-006 (HGG) and CT-005 (HNC): the upper end assumes positive data and higher approval probabilities, the lower end weaker data and delays.

Valuation and methodology

Our valuation is based on a risk-adjusted SOTP NPV (16.5% WACC, 1.3 equity beta and a 5% liquidity premium).

Key metrics

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB